Palisade Bio to Participate in the 2024 Maxim Healthcare Virtual Summit, Presented by Maxim Group LLC
– Live webcast fireside chat on Tuesday, October 15th at 4:30 PM ET Carlsbad, CA, Oct. 08, 2024 (GLOBE NEWSWIRE) --...
Day: October 8, 2024
MediWound to Participate in the 2024 Maxim Healthcare Virtual Summit
YAVNE, Israel, Oct. 08, 2024 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a global leader in next-generation enzymatic therapeutics for...
SIGA Announces Agreement to Supply TPOXX® in Morocco
NEW YORK, Oct. 08, 2024 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company and leader...
MiNK Therapeutics and Autonomous Therapeutics Announce Collaboration to Develop Novel Therapies Targeting Metastatic Tumors
NEW YORK, Oct. 08, 2024 (GLOBE NEWSWIRE) -- MiNK Therapeutics (MiNK, NASDAQ: INKT) a clinical-stage company pioneering the development of...
Streamline Health® Debuts eValuator™ Quality Module
eValuator Quality Module provides real-time risk scoring and quality measurement impact, and has already been implemented in a leading health...
Tourmaline Bio Announces Formation of Cardiovascular Scientific Advisory Board
– Tourmaline assembles leading experts to support the development of pacibekitug for cardiovascular diseases – – Cardiovascular Scientific Advisory Board...
Traws Pharma Announces Positive Topline Phase 1 Data for Flu Candidate, Tivoxavir Marboxil
Investigational agent in development as a one dose treatment or prevention of seasonal and pandemic influenza A dose ranging, Phase...
Vivos Therapeutics Granted CPT® Coverage and Reimbursement Codes for All Vivos CARE Oral Medical Devices From American Medical Association
New Medical Codes will Facilitate Billing by Commercial Payers for Vivos CARE Treatment for Obstructive Sleep Apnea in Adults and...
New Higher Dose Nusinersen Efficacy and Safety Data Presented at World Muscle Society Congress, Highlight Potential to Maximize Benefit of Nusinersen in SMA
Findings from Part B and Part C of the DEVOTE study support the clinical benefits of a higher dose regimen...
COSCIENS Biopharma Announces Change to Board of Directors
TORONTO, ONTARIO, Oct. 08, 2024 (GLOBE NEWSWIRE) -- COSCIENS Biopharma Inc. (NASDAQ: CSCI) (TSX: CSCI) (“COSCIENS” or the “Company”), a...
Amwell expands clinical programs portfolio to include Hello Heart cardiovascular health risk management solution
Hello Heart selects Amwell platform to extend its reach across patient populationsBOSTON and MENLO PARK, Calif., Oct. 08, 2024 (GLOBE...
Accolade Announces Results for Fiscal Second Quarter 2025
SEATTLE, Oct. 08, 2024 (GLOBE NEWSWIRE) -- Accolade, Inc. (NASDAQ: ACCD) today announced financial results for the fiscal second quarter...
Mestag Therapeutics Announces License and Research Collaboration with MSD to Identify Novel Targets for Inflammatory Diseases
Exclusively deploys Mestag’s proprietary RAFT platform to interrogate the pathogenic role of fibroblasts in inflammatory disease for novel target discoveryCAMBRIDGE,...
Avextra Announces the Approval of NEUROBIS by the Italian Medicines Agency: A Phase II Clinical Trial Using a Proprietary Cannabis-based Medicine for the Treatment of the Symptoms of Neurodegenerative Diseases
The Italian Medicines Agency AIFA and the Italian Ministry of Health have granted formal approval for NEUROBIS; a multi-centre Phase...
Teva Prolia® (Denosumab) Biosimilar Candidate is Accepted for Review by U.S. FDA and EU EMA
Prolia® (denosumab) is indicated to treat certain conditions that lead to high risk for fracture, including osteoporosis in postmenopausal womenTVB-009P,...
Bio-Path Holdings Initiates Development of Therapeutic Program for Treatment of Obesity
HOUSTON, Oct. 08, 2024 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilize® liposomal delivery...
Avalo Announces First Patient Dosed in Phase 2 LOTUS Trial of AVTX-009 for the Treatment of Hidradenitis Suppurativa
Global study in approximately 180 adults with hidradenitis suppurativa to assess the efficacy and safety of two dose regimens of...
Diagonal Therapeutics to Present at the Cure HHT’s 15th International Scientific Conference
Diagonal is advancing its lead program to treat the underlying cause of hereditary hemorrhagic telangiectasia (HHT)WATERTOWN, Mass., Oct. 08, 2024...
KSQ Therapeutics Appoints Anna Truppel-Hartmann, M.D., as Chief Medical Officer
LEXINGTON, Mass., Oct. 08, 2024 (GLOBE NEWSWIRE) -- KSQ Therapeutics, Inc. (KSQ), a clinical-stage biotechnology company developing novel treatments for...
VitalHub Completes Acquisition of MedCurrent Corporation
TORONTO, Oct. 08, 2024 (GLOBE NEWSWIRE) -- VitalHub Corp. (TSX: VHI) (OTCQX: VHIBF) (“VitalHub” or the “Company”) is pleased to...